C. Rosak

587 total citations
36 papers, 218 citations indexed

About

C. Rosak is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, C. Rosak has authored 36 papers receiving a total of 218 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Endocrinology, Diabetes and Metabolism, 13 papers in Molecular Biology and 9 papers in Surgery. Recurrent topics in C. Rosak's work include Metabolism, Diabetes, and Cancer (12 papers), Diabetes Management and Research (9 papers) and Diabetes Treatment and Management (9 papers). C. Rosak is often cited by papers focused on Metabolism, Diabetes, and Cancer (12 papers), Diabetes Management and Research (9 papers) and Diabetes Treatment and Management (9 papers). C. Rosak collaborates with scholars based in Germany, Estonia and Austria. C. Rosak's co-authors include Claudius Teupe, Κ. Schöffling, P.-H. Althoff, Ulrich Hofmann, Tjark Reblin, D. Seidel, Jens Werner, F. Enzmann, Robert Wolf and R. Petzoldt and has published in prestigious journals such as Diabetes Care, Diabetologia and European Journal of Endocrinology.

In The Last Decade

C. Rosak

32 papers receiving 200 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Rosak Germany 8 128 64 56 37 24 36 218
M. Yoshinari Japan 7 136 1.1× 36 0.6× 73 1.3× 35 0.9× 24 1.0× 13 224
Mamiko Tsugawa Japan 11 215 1.7× 77 1.2× 56 1.0× 69 1.9× 17 0.7× 21 324
H.‐J. Lisch Austria 8 186 1.5× 59 0.9× 58 1.0× 105 2.8× 25 1.0× 34 349
Guillausseau Pj France 8 146 1.1× 54 0.8× 18 0.3× 43 1.2× 7 0.3× 27 327
Rose Perich Australia 10 103 0.8× 117 1.8× 234 4.2× 36 1.0× 30 1.3× 19 347
Yoshie Arai Japan 7 110 0.9× 91 1.4× 187 3.3× 42 1.1× 16 0.7× 9 305
Monique G. de Sain-van der Velden Netherlands 8 59 0.5× 64 1.0× 33 0.6× 97 2.6× 6 0.3× 11 258
Aditya Goud United States 9 169 1.3× 110 1.7× 80 1.4× 109 2.9× 42 1.8× 24 332
Ryoichi Ishibashi Japan 9 83 0.6× 78 1.2× 18 0.3× 53 1.4× 19 0.8× 28 237
Dzau Vj United States 10 74 0.6× 118 1.8× 174 3.1× 43 1.2× 19 0.8× 15 311

Countries citing papers authored by C. Rosak

Since Specialization
Citations

This map shows the geographic impact of C. Rosak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Rosak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Rosak more than expected).

Fields of papers citing papers by C. Rosak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Rosak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Rosak. The network helps show where C. Rosak may publish in the future.

Co-authorship network of co-authors of C. Rosak

This figure shows the co-authorship network connecting the top 25 collaborators of C. Rosak. A scholar is included among the top collaborators of C. Rosak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Rosak. C. Rosak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Teupe, Claudius & C. Rosak. (2012). Diabetic cardiomyopathy and diastolic heart failure – Difficulties with relaxation. Diabetes Research and Clinical Practice. 97(2). 185–194. 36 indexed citations
2.
Schernthaner, G., Thomas Först, Dietrich C. Gulba, et al.. (2009). Herausforderung Diabetestherapie: Effekte der Glitazone jenseits der Blutzuckerkontrolle. DMW - Deutsche Medizinische Wochenschrift. 134(18). 949–954. 3 indexed citations
3.
Rosak, C., R. T. Jung, & Ulrich Hofmann. (2008). Insulin Glargine Maintains Equivalent Glycemic Control and Better Lipometabolic Control than NPH Insulin in Type 1 Diabetes Patients Who Missed a Meal. Hormone and Metabolic Research. 40(8). 544–548. 2 indexed citations
4.
Bachmann, W. E., et al.. (2008). Wirksamkeit der Kombinationsbehandlung mit Glibenclamid und Insulin bei Sulfonylharnstoff-Sekundärversagen: Kontrollierte multizentrische doppelblinde klinische Prüfung. DMW - Deutsche Medizinische Wochenschrift. 113(16). 631–636. 2 indexed citations
5.
Rosak, C., W. E. Bachmann, F. A. Gries, et al.. (2008). Klinische Erprobung eines neuen Blutzuckermeßsystems: Eine kooperative Studie in acht Zentren. DMW - Deutsche Medizinische Wochenschrift. 112(12). 466–470. 1 indexed citations
6.
Rosak, C., Eberhard Standl, Tjark Reblin, Holger Stammer, & D. Seidel. (2006). Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes. International Journal of Clinical Practice. 60(9). 1040–1047. 7 indexed citations
7.
Rosak, C., R. Petzoldt, Robert Wolf, et al.. (2005). Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes. International Journal of Clinical Practice. 59(10). 1131–1136. 20 indexed citations
8.
Rosak, C.. (2002). [When diet and oral antidiabetics are no longer enough. Optimal management of the diabetic patient with insulin].. PubMed. 144(18). 28–30, 32, 34. 2 indexed citations
9.
Rosak, C., et al.. (2002). The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.. PubMed. 15(3). 143–51. 17 indexed citations
10.
Rosak, C.. (2001). Insulinanaloga: Struktur, Eigenschaften und therapeutische Indikationen. Der Internist. 42(11). 1523–1535. 6 indexed citations
11.
Rosak, C., et al.. (1995). The Effect of the Timing and the Administration of Acarbose on Postprandial Hyperglycaemia. Diabetic Medicine. 12(11). 979–984. 18 indexed citations
12.
Boehm, B. O., Burkhard Manfras, C. Rosak, Κ. Schöffling, & Massimo Trucco. (1991). Aspartic acid at position 57 of the HLA-DQβ chain is protective against future development of insulin-dependent (Type 1) diabetes mellitus. Journal of Molecular Medicine. 69(4). 146–150. 3 indexed citations
13.
Althoff, P.-H., C. Rosak, W. Weichert, et al.. (1987). Spontaneous platelet aggregation and coagulation parameters as risk factors for arterial occlusions in diabetics. Results of the PARD-study.. PubMed. 5(3). 181–95. 19 indexed citations
14.
15.
Althoff, P.-H., C. Rosak, W. Weichert, et al.. (1986). Haemostasiological parameters as risk factor for new arterial occlusions in diabetics.. PubMed. 64(20). 1042–6. 7 indexed citations
16.
Jungmann, E, et al.. (1986). [Increased endogenous dopamine activity in diabetes mellitus. Inhibition of plasma renin activity, aldosterone and prolactin secretion].. PubMed. 104(45). 869–70. 2 indexed citations
17.
Cugini, P, P Lucia, Claudio Letizia, et al.. (1985). Temporal correlation of some endocrine circadian rhythms in elderly subjects. Maturitas. 7(2). 175–186. 5 indexed citations
18.
Rosak, C., P.-H. Althoff, F. Enzmann, & Κ. Schöffling. (1982). Comparative Studies on Intermediary Metabolism and Hormonal Counterregulation Following Human Insulin (recombinant DNA) and Purified Pork Insulin in Man. Diabetes Care. 5(Supplement_2). 82–89. 17 indexed citations
19.
Rosak, C. & Κ. Schöffling. (1977). [Effect of Diclofenac on glucose tolerance of diabetic patients].. PubMed. 28(45). 1845–6. 4 indexed citations
20.
Rosak, C., et al.. (1972). Studies on the site of action of tolbutamide in the lipolytic system. Diabetologia. 8(3). 185–188. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Yoshinari Breakdown of academic impact, for papers by Mamiko Tsugawa Breakdown of academic impact, for papers by H.‐J. Lisch Breakdown of academic impact, for papers by Guillausseau Pj Breakdown of academic impact, for papers by Rose Perich Breakdown of academic impact, for papers by Yoshie Arai Breakdown of academic impact, for papers by Monique G. de Sain-van der Velden Breakdown of academic impact, for papers by Aditya Goud Breakdown of academic impact, for papers by Ryoichi Ishibashi Breakdown of academic impact, for papers by Dzau Vj
Rankless by CCL
2026